India, Oct. 5 -- AIM ImmunoTech Inc. (AIM) on Monday highlighted recent media coverage of Ampligen (rintatolimod), the company's investigational broad-spectrum antiviral and immunomodulatory therapy.
The coverage focused on Ampligen's potential applications in antiviral preparedness and biodefense, including its possible use against emerging viral threats such as Ebola virus disease.
Ampligen is a double-stranded RNA and highly selective TLR3 agonist designed to enhance the body's innate immune response against viral threats.
AIM said recent coverage also highlighted the company's expanding intellectual property portfolio covering Ampligen's potential applications in Long COVID and other post-viral conditions.
The company noted that Amp...